ATE306931T1 - Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer - Google Patents

Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer

Info

Publication number: ATE306931T1
Authority: AT; Austria
Prior art keywords: beta; alzheimer; amyloid; suppression; changes associated
Prior art date: 1997-12-03

Application number

AT98961894T

Other languages

English (en)

Inventor

Howard L Weiner

Dennis J Selkoe

Original Assignee

Neuralab Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-03

Filing date

1998-12-03

Publication date

2005-11-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26747618&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE306931(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-12-03 Application filed by Neuralab Ltd filed Critical Neuralab Ltd

2005-11-15 Application granted granted Critical

2005-11-15 Publication of ATE306931T1 publication Critical patent/ATE306931T1/de

Links

102000013455 Amyloid beta-Peptides Human genes 0.000 title 1
108010090849 Amyloid beta-Peptides Proteins 0.000 title 1
230000001629 suppression Effects 0.000 title 1
239000002552 dosage form Substances 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Gastroenterology & Hepatology (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Marine Sciences & Fisheries (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)
Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
Engine Equipment That Uses Special Cycles (AREA)
Steroid Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT98961894T 1997-12-03 1998-12-03 Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer ATE306931T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US6721997P	1997-12-03	1997-12-03
US7969798P	1998-03-27	1998-03-27
PCT/US1998/025694 WO1999027949A1 (en)	1997-12-03	1998-12-03	METHOD OF SUPPRESSING β-AMYLOID-RELATED CHANGES IN ALZHEIMER'S DISEASE

Publications (1)

Publication Number	Publication Date
ATE306931T1 true ATE306931T1 (de)	2005-11-15

Family

ID=26747618

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98961894T ATE306931T1 (de)	1997-12-03	1998-12-03	Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer

Country Status (8)

Country	Link
EP (1)	EP1033998B1 (de)
JP (2)	JP2002511385A (de)
AT (1)	ATE306931T1 (de)
AU (1)	AU742970C (de)
CA (1)	CA2312475C (de)
DE (2)	DE69831971T2 (de)
ES (1)	ES2253839T3 (de)
WO (1)	WO1999027949A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997021728A1 (en)	1995-12-12	1997-06-19	Karolinska Innovations Ab	PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US6913745B1 (en)	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease
US6787523B1 (en)	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
US6905686B1 (en)	1997-12-02	2005-06-14	Neuralab Limited	Active immunization for treatment of alzheimer's disease
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en)	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
US6923964B1 (en)	1997-12-02	2005-08-02	Neuralab Limited	Active immunization of AScr for prion disorders
US7588766B1 (en)	2000-05-26	2009-09-15	Elan Pharma International Limited	Treatment of amyloidogenic disease
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en)	1997-12-02	2004-06-15	Neuralab Limited	Humanized and chimeric N-terminal amyloid beta-antibodies
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
EP1033998B1 (de) *	1997-12-03	2005-10-19	Neuralab, Ltd.	Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
US20030147882A1 (en)	1998-05-21	2003-08-07	Alan Solomon	Methods for amyloid removal using anti-amyloid antibodies
US7060670B1 (en)	1999-05-05	2006-06-13	Neurochem (International) Limited	Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US6787637B1 (en)	1999-05-28	2004-09-07	Neuralab Limited	N-Terminal amyloid-β antibodies
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
US6713450B2 (en)	2000-05-22	2004-03-30	New York University	Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid β for induction of an immune response to amyloid β and amyloid deposits
EP1309341A2 (de)	2000-07-07	2003-05-14	Lars Lannfelt	Prävention und behandlung der alzheimer krankheit
TWI255272B (en)	2000-12-06	2006-05-21	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
US7264810B2 (en)	2001-01-19	2007-09-04	Cytos Biotechnology Ag	Molecular antigen array
US7479482B2 (en)	2001-11-21	2009-01-20	New York University	Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid β, prion protein, amylin, α-synuclein, or polyglutamine repeats for induction of an immune response thereto
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
SI1524994T1 (sl)	2002-07-19	2011-08-31	Cytos Biotechnology Ag	Sestavki cepiv, ki vsebujejo amiloidne beta 1-6 antigenske mreĹľe
WO2004056318A2 (en)	2002-12-19	2004-07-08	New York University	Method for treating amyloid disease
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PE20050627A1 (es)	2003-05-30	2005-08-10	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido beta amiloideo
SE0401601D0 (sv)	2004-06-21	2004-06-21	Bioarctic Neuroscience Ab	Protofibril specific antibodies and uses thereof
GB0424563D0 (en)	2004-11-05	2004-12-08	Novartis Ag	Organic compounds
TW200636066A (en)	2004-12-15	2006-10-16	Elan Pharm Inc	Humanized antibodies that recognize beta amyloid peptide
WO2006066089A1 (en)	2004-12-15	2006-06-22	Neuralab Limited	Humanized amyloid beta antibodies for use in improving cognition
GT200600031A (es)	2005-01-28	2006-08-29		Formulacion anticuerpo anti a beta
RU2432362C2 (ru)	2005-11-30	2011-10-27	Эбботт Лэборетриз	Моноклональные антитела и их применения
PL2289909T3 (pl)	2005-11-30	2015-04-30	Abbvie Inc	Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
RU2429244C2 (ru)	2006-03-23	2011-09-20	Байоарктик Ньюросайенс Аб	Улучшенные селективные в отношении протофибрилл антитела и их применение
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (de)	2007-02-27	2009-12-02	Abbott GmbH & Co. KG	Verfahren zur behandlung von amyloidosen
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
PT2182983E (pt)	2007-07-27	2014-09-01	Janssen Alzheimer Immunotherap	Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
ES2684475T3 (es)	2010-04-15	2018-10-03	Abbvie Inc.	Proteínas que se unen a beta amiloide
CN103298833B (zh)	2010-08-14	2015-12-16	Abbvie公司	β淀粉样蛋白结合蛋白
WO2013012811A2 (en)	2011-07-19	2013-01-24	New York University	Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
WO2013013056A1 (en)	2011-07-19	2013-01-24	New York University	Method for treating amyloid disease
US20150290158A1 (en) *	2012-11-09	2015-10-15	Elliott C. Lasser	X-ray contrast media compositions and methods of using the same to treat, reduce or delay the onset of cns inflammation and inflammation associated conditions
EP3166970B1 (de)	2014-07-10	2021-03-10	BioArctic AB	Verbesserte ass-protofibrilenbindende antikörper

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5223482A (en) *	1986-11-17	1993-06-29	Scios Nova Inc.	Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
ATE153534T1 (de) *	1990-04-27	1997-06-15	John Mcmichael	Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein
AU686818B2 (en) *	1994-05-25	1998-02-12	John Mcmichael	Materials and methods for treatment of plaquing diseases
WO1996039176A1 (en) *	1995-06-05	1996-12-12	Brigham & Women's Hospital	USE OF ORAL TOLERANCE TO SUPPRESS BOTH Th1 AND Th2 IMMUNE RESPONSES AND TO SUPPRESS ANTIBODY PRODUCTION
WO1997018855A1 (en) *	1995-11-21	1997-05-29	Eduard Naumovich Lerner	Device for enhanced delivery of biologically active substances and compounds in an organism
ZA97452B (en) *	1996-01-25	1997-08-15	Trinity College Dublin	Streptococcus equi vaccine.
JPH09208485A (ja) *	1996-01-31	1997-08-12	Teijin Ltd	ペプチド・蛋白質性薬物の水難溶性組成物
EP1033998B1 (de) *	1997-12-03	2005-10-19	Neuralab, Ltd.	Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer

1998
- 1998-12-03 EP EP98961894A patent/EP1033998B1/de not_active Expired - Lifetime
- 1998-12-03 DE DE69831971T patent/DE69831971T2/de not_active Expired - Lifetime
- 1998-12-03 DE DE1033998T patent/DE1033998T1/de active Pending
- 1998-12-03 ES ES98961894T patent/ES2253839T3/es not_active Expired - Lifetime
- 1998-12-03 AT AT98961894T patent/ATE306931T1/de not_active IP Right Cessation
- 1998-12-03 WO PCT/US1998/025694 patent/WO1999027949A1/en not_active Ceased
- 1998-12-03 CA CA2312475A patent/CA2312475C/en not_active Expired - Lifetime
- 1998-12-03 AU AU17099/99A patent/AU742970C/en not_active Expired
- 1998-12-03 JP JP2000522934A patent/JP2002511385A/ja active Pending
2010
- 2010-04-02 JP JP2010086400A patent/JP2010215627A/ja active Pending

Also Published As

Publication number	Publication date
AU1709999A (en)	1999-06-16
JP2002511385A (ja)	2002-04-16
CA2312475C (en)	2010-08-03
ES2253839T3 (es)	2006-06-01
EP1033998B1 (de)	2005-10-19
DE69831971T2 (de)	2006-07-06
EP1033998A1 (de)	2000-09-13
DE1033998T1 (de)	2001-05-23
JP2010215627A (ja)	2010-09-30
AU742970C (en)	2003-03-20
AU742970B2 (en)	2002-01-17
WO1999027949A1 (en)	1999-06-10
WO1999027949A9 (en)	1999-09-10
CA2312475A1 (en)	1999-06-10
DE69831971D1 (de)	2006-03-02
EP1033998A4 (de)	2003-06-04

Legal Events

Date	Code	Title	Description
2006-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE306931T1 (de)	2005-11-15	Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
EP0552256A4 (de)	1994-04-27
GEP20053715B (en)	2005-12-26	Prevention and Treatment of Amyloidogenic Disease
DE69331409D1 (de)	2002-02-07	Oral 1alpha-hydroxyprevitamin d
YU59092A (sh)	1994-12-28	Formulacije aerosola koji ne sadrže hlorofluorougljenična jedinjenja
SE9703191D0 (sv)	1997-09-04	Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases
ATE338771T1 (de)	2006-09-15	Antagonisten des intestinotrophen glp-2 peptides
WO1994027589A3 (en)	1995-01-26	Antidepressant dosage form
EP1024827A4 (de)	2002-08-28	Zusammensetzungen und methoden zur systemischen verabreichung von oralen impfstoffen und therapeutischen wirkstoffen
ATE234602T1 (de)	2003-04-15	Verabreichungsform zur abgabe von steigenden wirkstoffdosen
DE3875108D1 (de)	1992-11-05	Physiologisch aktives polypeptid und pharmazeutische komposition.
IT1222395B (it)	1990-09-05	Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare
GR1000419B (el)	1992-06-30	Μορφη δοσολογιας για χορηγηση ανταγωνιστη του ασβεστιου.
NO943288L (no)	1995-03-22	Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
TR200000455T2 (tr)	2000-09-21	Alzheimer hastalığının tedavisinde fankinonun kullanılması.
MX9707642A (es)	1997-12-31	Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
PT1150703E (pt)	2006-05-31	Terapia de esclerose multipla com chaperonina 10 e beta-interferao
BG103905A (en)	2000-07-31	New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
DE69314586D1 (de)	1997-11-20	Arzneimittelzusammensetzung enthaltend TCF-II
MY112888A (en)	2001-10-31	Use of bradykinin antagonists for the preparation of medicaments for the treatment of virus diseases.
GR3035004T3 (en)	2001-03-30	Method and composition for the treatment of herpes related disorders.
DE59410137D1 (de)	2002-07-18	Neue pharmazeutische zubereitungen zur oralen verabreichung enthaltend cyclosporin
DE69822234D1 (de)	2004-04-08	Verwendung von Olanzapin zur Herstellung eines Arzneimittels zur Neuroprotektion
TH19526A (th)	1996-07-16	วิธีการและสารผสมสำหรับรักษาโรคตับอักเสบชนิดออโตอิมมูน